Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Winny Chan
Institution:
Taiho Oncology (United States)
Observed institutions:
University of the Pacific,
Vanderbilt University,
Fred Hutch Cancer Center,
CTI BioPharma (United States),
Azienda Ospedaliero-Universitaria Careggi,
Taiho Oncology (United States),
Astex Pharmaceuticals,
Vanderbilt-Ingram Cancer Center,
University of Florence
show all 9
OpenAlex ID:
A5058326151
Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial
2019
·
Sachin A. Shah
, Andy H. Szeto
, et al.
·
Journal of the American Heart Association
·
111
Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
2022
·
Michael R. Savona
, James K McCloskey
, et al.
·
Blood
·
12
Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine
2023
·
Guillermo Garcia-Manero
, James McCloskey
, et al.
·
Blood
·
4
MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
2023
·
Guillermo Garcia-Manero
, Kimo Bachiashvili
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
3
PDF
P735: Efficacy and Safety of Oral Decitabine/cedazuridine (astx727) in the Cmml Subpopulation From Phase 2 and Ascertain Phase 3 Studies
2023
·
Michael Robert Savona
, James K Mccloskey
, et al.
·
HemaSphere
·
2
Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes
2025
·
Guillermo Garcia-Manero
, Lalit Saini
, et al.
·
Blood
·
1
MDS-773 Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine
2024
·
Guillermo Garcia-Manero
, James McCloskey
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine
2024
·
Guillermo Garcia-Manero
, James McCloskey
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems
2023
·
Guillermo Garcia-Manero
, James McCloskey
, et al.
·
Blood
PDF
POSTER: MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
2023
·
Guillermo Garcia-Manero
, Kimo Bachiashvili
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-634 Efficacy and Safety of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subpopulation from Phase 2 and ASCERTAIN Phase 3 Studies
2023
·
Michael R. Savona
, James K. McCloskey
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PDF
MDS-634 Efficacy and Safety of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subpopulation from Phase 2 and ASCERTAIN Phase 3 Studies
2023
·
Michael R. Savona
, James K. McCloskey
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PDF
Show more works
View as search
Works count:
12
Citation count:
133
H-index:
3
I10-index:
2
Year
Topic
Type
